Activity of the colistin–rifampicin combination against colistin-resistant, carbapenemase-producing Gram-negative bacteria

References

• Walsh T. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents. 2010;36(3):8–14.
   Google Scholar
• Falagas ME, Bliziotis I. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents. 2007;29:630–6.
   PubMed Web of Science ®Google Scholar
• Thiolas A, Bollet C, La Scola B, Raoult D, Pages JM. Successive emergence of Enterobacter aerogenes strains resistant to imipenem and colistin in a patient. Antimicrob Agents Chemother. 2005;49:1354–8.
   PubMed Web of Science ®Google Scholar
• Lee J, Patel G, Huprikar S, Calfee D, Jenkins S. Decreased susceptibility to Polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. Clin Microbiol. 2009;47:1611–12.
   Web of Science ®Google Scholar
• David M, Gill M. Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin. J Antimicrob Chemother. 2008;61:962–4.
   PubMed Web of Science ®Google Scholar
• Elemam A, Rahimian J, Mandell W. Infection with pan resistant Klebsiella pneumoniae: a report of 2 cases and brief review of the literature. Clin Infect Dis. 2009;49:271–4.
   PubMed Web of Science ®Google Scholar
• Eleman MA, Rahimian J, Doymaz M. In vitro evaluation of antibiotic synergy for polymyxin-resistant carbapenemase producing Klebsiella pneumoniae. J Clin Microbiol. 2010;48:3558–62.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 22nd Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2012, M100-S22.
   Google Scholar
• Members of the SFM Antibiogram Committee. Comite de l’Antibiogramme de la Société Française de Microbiologie report. Int J Antimicrob Agents. 2003;21:364–91.
   PubMedGoogle Scholar
• Bradford PA. Tigecycline: a first in class glycylcycline. Clin Microbiol Newsl. 2004;26:163–8.
   Google Scholar
• Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70:119–23.
   PubMed Web of Science ®Google Scholar
• Woodford N, Ellington M, Coehlo J, Turton J, Ward M, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006;27:351–3.
   PubMed Web of Science ®Google Scholar
• Limansky AS, Viale A. Can composition and structural features of oligonucleotides contribute to their wide-scale applicability as random PCR primers in mapping bacterial genome diversity? J Microbiol Methods. 2002;50:291–7.
   PubMed Web of Science ®Google Scholar
• Wareham DW, Bean DC. In vitro activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2006;50:825–6.
   PubMed Web of Science ®Google Scholar
• Rodriguez CH, De Ambrosio A, Bajuk M, Spinozzi M, Nastro M, Bombicino K, et al. In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J Infect Dev Ctries. 2010;4:164–7.
   PubMed Web of Science ®Google Scholar
• Endimiani A, Patel G, Hujer K, Swaminathan M, Perez F, Rice L, et al. In vitro activity of fosfomycin against bla-KPC – containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother. 2010;54:1526–9.
   PubMedGoogle Scholar
• Marchaim D, Chopra T, Pogue JM, Perez F, Hujer AM, Rudin S, et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother. 2011;55:593–9.
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Galani L, Baziaka F, Karaiskos I. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2013;57(5):2388–90.
   PubMed Web of Science ®Google Scholar
• Ceccarelli G, Falcone M, Giordano A, Mezzatesta ML,Caio C, Stefani S, et al. Successful ertapenem–doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2013;57(6):2900–01.
   PubMed Web of Science ®Google Scholar
• Bulik C, Nicolau P. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumonia. Antimicrob. Agents Chemother. 2011;55:3002–04.
   PubMed Web of Science ®Google Scholar
• Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobials strategies. J Antimicrob Chemother. 2012;67:1607–15.
   PubMed Web of Science ®Google Scholar
• Fernandez-Reyes M, Rodriguez-Falcon M, Chiva C, Pachon J, Andreu D, Rivas L. The cost of resistance to colistin in Acinetobacter baumannii: in a proteomic perspective. Proteomics. 2009;9:1632–45.
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Chinello P, Proietti MF, Cecchini L, Masala M, Franchi C, et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect. 2005;11:682–4.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karageorgopoulos DE, Nordmann P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol. 2011;6:653–66.
   PubMed Web of Science ®Google Scholar
• Jernigan MG, Press EG, Nguyen MH, Clancy CJ, Shields RK. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2012;56:3395–8.
   PubMed Web of Science ®Google Scholar
• Vidaillac C, Benichou L, Duval RE. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2012;56:4856–61.
   PubMed Web of Science ®Google Scholar
• Peck KR, Kim MJ, Choi JY, Kim HS, Kang CI, Cho YK, et al. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates. J Med Microbiol. 2012;61:353–60.
   PubMed Web of Science ®Google Scholar
• Bratu S, Tolaney P, Karumucdi U, Quale J, Mooty M, Nichani S, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother. 2005;56:1128–32.
   Google Scholar
• Yoon J, Urban C, Terzian C, Mariano N, Rahan J. ‘In vitro’ double and triple synergistic activities of polymyxin B, imipenem, and rifampicin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004;48:753–7.
   PubMed Web of Science ®Google Scholar
• Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis. 2000;31:101–6.
   PubMed Web of Science ®Google Scholar
• Ostenson RC, Fields BT, Nolan CM. Polymyxin B and rifampin: new regimen for multiresistant Serratia marcescens infections. Antimicrob Agents Chemother. 1977;12:655–9.
   PubMed Web of Science ®Google Scholar
• Bergen PL, Landersdorfer CB, Zhong J, Zhoo M, Lee HJ, Nation RL, et al. Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new. Diagn Microbiol Infect Dis. 2012;34:213–23.
   Google Scholar